On January 29, 2021, Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB) announced the completion of its acquisition of Quellis Biosciences, Inc. Concurrent with the closing of the transaction, an investor syndicate led by Perceptive Advisors, with participation from Fairmount Funds, RA Capital, Cormorant, Venrock, Logos, Boxer, Acorn, Commodore, Surveyor, Acuta, Sphera, and Serrado invested approximately $110 million in the company. Catabasis expects to use the proceeds from the private placement primarily to enable the completion of IND-enabling studies, Phase 1a, and Phase 1b/2 clinical trials for the lead program QLS-215 in hereditary angioedema (HAE), a rare, debilitating and potentially life-threatening disease.
Ladenburg Thalmann & Co. Inc. acted as the Exclusive Financial Advisor to Catabasis in its acquisition of Quellis.
About Catabasis Pharmaceuticals
Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB) is a biotechnology company focused on developing therapies for patients affected by rare diseases. It's lead program, QLS-215, is a potential best-in-class plasma kallikrein monoclonal antibody in preclinical development for the treatment of Hereditary Angioedema. For more information, please visit the company's website at www.catabasis.com.
The information and material presented is provided for informational purposes only and are not to be used or considered as an offer or the solicitation of an offer to sell or buy any securities mentioned herein.